Despite disagreeing with accusations that it fails to comply with regulatory practices, Akorn is something of a full employment act for Food and Drug Administration inspectors.
The agency released another in an ongoing stream of inspection reports that have found quality control problems at different Akorn plants in the U.S. and elsewhere. The concerns included a failure to review unexplained discrepancies in batches and consistently investigate issues with batch samples; procedures for quality control were not in writing; and a failure to validate procedures to avoid contamination.
About the Author Reprints
